Syncona is a leading FTSE250 company focused on founding, building and funding global leaders in life science
Investors
We aim to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.
Net assets
£1340m
Fully diluted NAV per share
199.4p
Life science portfolio value
£517m
Capital pool supporting investment in life science
£823m
Portfolio snapshot
- 13 portfolio companies in innovative areas of life science
- 700+ employees across Syncona portfolio
- 7 live clinical trials across the portfolio
Company news alerts
Sign up to get the latest RNS, company news, share price information and results from Syncona.
